home All News open_in_new Full Article

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026

New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs LIKMEZ® (ATI-1501): Building Commercial Momentum in the U.S. Through Re-Launch and Increasing Sales Growth HALIFAX, Nova Scotia, Nov. 13, 2025 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a […]


today 3 d. ago attach_file Culture

attach_file Culture
attach_file Economics
attach_file Culture
attach_file Culture
attach_file Sport
attach_file Politics
attach_file Culture
attach_file Society
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Other
attach_file Society
attach_file Culture
attach_file Other
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Sport


ID: 3244456800
Add Watch Country

arrow_drop_down